Dr. Kato on the Rationale For Investigating Dato-DXd Plus Durvalumab and Carboplatin in Advanced NSCLC

Terufumi Kato, MD, Terufumi Kato, MD, Chief Physician, Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan, discusses the ongoing investigation of datopotamab deruxtecan in combination with durvalumab and carboplatin as a first-line treatment for patients with advanced metastatic non–small cell lung cancer.

Related Keywords

Kanagawa , Fukushima , Japan , Yokohama , Terufumi Kato , Kanagawa Cancer Center , Department Of Thoracic Oncology , Chief Physician , Thoracic Oncology , Infinatamab Deruxtecan , I Dxd Ds 7300 , 2023 Iaslc World Conference On Lung Cancer , Dato Dxd , Durvalumab , Carboplatin , Non Small Cell Lung Cancer ,